Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

This article discusses emerging concerns about secondary T-cell cancers following treatment with chimeric antigen receptor (CAR) T cell therapies. While these therapies have revolutionized care for relapsed or refractory hematologic cancers, the FDA has identified 22 cases of T-cell malignancies post-treatment, with genetic evidence linking some cancers to the CAR construct itself. The article emphasizes the need for lifelong monitoring of patients, improved genomic targeting strategies, and comprehensive tumor testing to better understand and mitigate oncogenic risks associated with CAR-T therapies.

This article discusses emerging concerns about secondary T-cell cancers following treatment with chimeric antigen receptor (CAR) T cell therapies. While these therapies have revolutionized care for relapsed or refractory hematologic cancers, the FDA has identified 22 cases of T-cell malignancies post-treatment, with genetic evidence linking some cancers to the CAR construct itself. The article emphasizes the need for lifelong monitoring of patients, improved genomic targeting strategies, and comprehensive tumor testing to better understand and mitigate oncogenic risks associated with CAR-T therapies.